Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer.
Saved in:
| Title: | Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer. |
|---|---|
| Authors: | van Amstel FJG; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., de Mooij CM; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Simons JM; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.; Department of Radiotherapy, Erasmus Medical Center, Rotterdam, The Netherlands., Mitea C; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Nelemans PJ; Department of Epidemiology, Maastricht University, Maastricht, The Netherlands., van der Pol CC; Department of Surgical Oncology, Alrijne Hospital, Leiderdorp, The Netherlands., Luiten EJT; Department of Surgery, Amphia Hospital Breda, Breda, The Netherlands.; Tawam Breast Care Center, Tawam Hospital, Al Ain, United Arab Emirates.; Department of Surgery, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Koppert LB; Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Smidt ML; Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. |
| Corporate Authors: | REFINE Study Group |
| Source: | The British journal of surgery [Br J Surg] 2024 Aug 30; Vol. 111 (9). |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press on behalf of BJS Foundation Ltd Country of Publication: England NLM ID: 0372553 Publication Model: Print Cited Medium: Internet ISSN: 1365-2168 (Electronic) Linking ISSN: 00071323 NLM ISO Abbreviation: Br J Surg Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
